Bookmark and Share

Carol O. Tacket

Carol O. Tacket M.D.

Academic Title: Adjunct Professor
Primary Appointment: Medicine

Personal History:

Dr. Tacket is an adjunct professor in the Department of Medicine.

Research Interests:

Dr. Tacket's primary research interest has been in conducting phase 1 and phase 2 studies of candidate vaccines against enteric infections. She has conducted numerous clinical studies evaluating novel ways to deliver vaccine antigens, such as via attenuated S. typhi, attenuated V cholerae, adenovirus, biodegradable microspheres, transgenic plants, and by DNA vaccination. Dr. Tacket has authored or co-authored more than 100 research papers and book chapters on infectious disease topics.

Clinical Speciality:

Infectious Diseases


Tacket CO, Sztein MB, Losonsky G, Abe A, Finlay BF, McNamara BP, Fantry GT, James SP, Nataro JP, Levine MM, Donnenberg MS. The role of EspB in experimental human enteropathogenic Escherichia coli (EPEC) infection, Infection and Immunity, 2000, 68, 3689-3695.94.
Tacket CO, Losonsky G, Estes MK, Levine MM, Kirk D, Mason HS, Arntzen CJ. Immunogenicity of recombinant norwalk virus capsid protein delivered in transgenic potatoes, Journal of Infectious Diseases, 2000, 182, 302-305.
Tacket CO, Galen J, Sztein MB, Losonsky G, Wyant T, Nataro J, Wasserman SS, Edelman R, Chatfield S, Dougan G, Levine MM. Safety and immune responses to attenuated Salmonella enterica serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C, Clinical Immunology, 2000, 96, 146-153.
Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal and cellular immune responses to oral Norwalk virus-like particles (VLP) in volunteers, Clinical Immunology, 2003,108, 241-247.
Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM. Immune responses to an oral typhoid vaccine strain modified to constitutively express Vi capsular polysaccharide. Journal of Infectious Diseases, 2004, 190, 565-570.
Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn, Vaccine, 2004, 22, 4385-4389.